JAMA Surg:胃腺癌手术后静脉血栓栓塞的预防

2018-07-21 zhangfan MedSci原创

研究认为,胃腺癌术后仅进行单纯的间歇气压治疗,对预防静脉血栓栓塞的效果劣于气压联合肝素治疗,但肝素治疗导致患者出血风险增加。未来术后VTE高风险患者的识别将成为研究的重点之一

美国国家综合癌症网络和美国临床肿瘤学协会的指南建议对胃腺癌手术患者术后进行常规血栓预防,但在许多亚洲国家中,胃癌手术后静脉血栓栓塞(VTE)预防的实施率较低。近日研究人员就韩国胃腺癌患者术后VTE发生率进行了考察,以评估VTE预防的必要性及安全性。

PROTECTOR研究中,经组织学确诊的胃腺癌患者参与研究,患者在术后随机接受间歇气压疗法(IPC)或IPC联合低分子量肝素钠(LMW)治疗,主要终点为术后VTE发生率。

682名患者参与研究,女性占34.5%,平均年龄57.67岁,666名患者完成研究。总的VTE发生率为2.1%,其中单纯IPC组患者VTE事件率高于肝素治疗组(3.6 vs 0.6%)。14名VTE患者中,13人无症状,为深静脉血栓患者,1例为有症状的肺血栓栓塞。出血并发症的总发生率为5.1%,肝素治疗组出血并发症率高于单纯IPC组(9. 1 vs 1.2%)。未发生VTE相关的患者死亡。

研究认为,胃腺癌术后仅进行单纯的间歇气压治疗,对预防静脉血栓栓塞的效果劣于气压联合肝素治疗,但肝素治疗导致患者出血风险增加。未来术后VTE高风险患者的识别将成为研究的重点之一。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697729, encodeId=02b0169e72900, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Mar 06 03:38:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955374, encodeId=af4119553e4ae, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Nov 23 16:38:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333712, encodeId=1e45333e1227, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 24 00:09:44 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305923, encodeId=f567130592389, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sun Jul 22 23:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333135, encodeId=14b733313568, content=学习了!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jul 21 09:52:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333121, encodeId=525533312138, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 21 08:50:50 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2019-03-06 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697729, encodeId=02b0169e72900, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Mar 06 03:38:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955374, encodeId=af4119553e4ae, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Nov 23 16:38:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333712, encodeId=1e45333e1227, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 24 00:09:44 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305923, encodeId=f567130592389, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sun Jul 22 23:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333135, encodeId=14b733313568, content=学习了!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jul 21 09:52:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333121, encodeId=525533312138, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 21 08:50:50 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-11-23 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697729, encodeId=02b0169e72900, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Mar 06 03:38:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955374, encodeId=af4119553e4ae, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Nov 23 16:38:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333712, encodeId=1e45333e1227, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 24 00:09:44 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305923, encodeId=f567130592389, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sun Jul 22 23:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333135, encodeId=14b733313568, content=学习了!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jul 21 09:52:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333121, encodeId=525533312138, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 21 08:50:50 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-24 明崖

    学习了,有用的研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1697729, encodeId=02b0169e72900, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Mar 06 03:38:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955374, encodeId=af4119553e4ae, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Nov 23 16:38:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333712, encodeId=1e45333e1227, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 24 00:09:44 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305923, encodeId=f567130592389, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sun Jul 22 23:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333135, encodeId=14b733313568, content=学习了!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jul 21 09:52:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333121, encodeId=525533312138, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 21 08:50:50 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1697729, encodeId=02b0169e72900, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Mar 06 03:38:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955374, encodeId=af4119553e4ae, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Nov 23 16:38:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333712, encodeId=1e45333e1227, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 24 00:09:44 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305923, encodeId=f567130592389, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sun Jul 22 23:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333135, encodeId=14b733313568, content=学习了!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jul 21 09:52:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333121, encodeId=525533312138, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 21 08:50:50 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 zb1235672

    学习了!!!!!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1697729, encodeId=02b0169e72900, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Mar 06 03:38:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955374, encodeId=af4119553e4ae, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Nov 23 16:38:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333712, encodeId=1e45333e1227, content=学习了,有用的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Tue Jul 24 00:09:44 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305923, encodeId=f567130592389, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sun Jul 22 23:38:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333135, encodeId=14b733313568, content=学习了!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jul 21 09:52:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333121, encodeId=525533312138, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 21 08:50:50 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

重复 NEJM:阿司匹林预防静脉血栓栓塞事件增添新证据

深静脉血栓形成(DVT)和肺栓塞(PE)通称为静脉血栓栓塞(VTE)是全髋或全膝关节成形手术的公认并发症。围手术期抗凝治疗被证明能够降低手术后VTE相关死亡和并发症。出院后延长时间预防也能获益,特别是全髋关节成形术的患者。对于全髋关节置换术或全膝关节置换术的患者,当前指南推荐预防性抗凝持续最少14天,建议应该预防持续到手术后35天。因为有效性、安全性和使用方便,直接口服抗凝剂常被用于长时间抗凝的选

J Thromb Haemost:年龄调整后的D-二聚体临界值对静脉血栓栓塞诊断更有效!

由此可见,年龄调整后临界值仍然可以保持较高的灵敏度,特异性适当改善。假阳性结果明显减少,这反映了避免了不必要的影像学检查。这表明年龄调整后临界值对于老年患者静脉血栓栓塞的治疗在临床和经济上都有好处。

J Rheumatol:系统性硬化症中的静脉血栓栓塞:患病率、危险因素和对生存率的影响

系统性硬化症患者出现静脉血栓栓塞的风险与一般人群相当。

2018 APAGBI指南:儿童患者围术期静脉血栓栓塞的预防

2018年4月,大不列颠爱尔兰儿科麻醉医师协会(APAGBI)发布了儿童患者围术期静脉血栓栓塞的预防指南,文章主要回顾了围术期静脉血栓栓塞的发生率,危险因素,预防措施以及相关并发症,并针对静脉血栓栓塞的预防提出指导建议。

2018 AORN指南:静脉血栓栓塞的预防(概要)

本文的主要目的是指导围手术期团队成员实施预防静脉血栓栓塞方案的措施,包括深静脉血栓形成的机械预防和药物预防以及深静脉血栓形成并发症肺栓塞的预防。

妊娠期及产褥期静脉血栓栓塞疾病诊治:2015英国皇家妇产科医师学会指南解读

2015年4月,英国皇家妇产科医师学会(Royal College of Obstetricians and Gynaecologists, ROCG)发布了关于降低妊娠期及产褥期静脉血栓栓塞疾病发生风险的诊疗指南(Green-top Guideline No.37a)。